Phase II clinical trial to evaluate safety and efficacy of mobilisation and collection of CD34+ cells after treatment with plerixafor and filgrastim in patients with Fanconi anaemia for subsequent transduction with a lentiviral vector carrying the FANCA gene and reinfusion into the patient

Trial Profile

Phase II clinical trial to evaluate safety and efficacy of mobilisation and collection of CD34+ cells after treatment with plerixafor and filgrastim in patients with Fanconi anaemia for subsequent transduction with a lentiviral vector carrying the FANCA gene and reinfusion into the patient

Not yet recruiting
Phase of Trial: Phase II

Latest Information Update: 08 Jul 2016

At a glance

  • Drugs Plerixafor (Primary) ; Filgrastim
  • Indications Fanconi's anaemia
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 08 Jul 2016 Planned initiation date changed from 15 Jun 2016 to 1 Aug 2016.
    • 20 Oct 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top